Personalized T cell therapy shows signs of clinical effectiveness against HBV-related HCC

April 12, 2018, Paris, France: Multiple adoptive transfers of T cells engineered to carry hepatitis B virus (HBV)-specific T cell receptors (TCRs) has resulted in an objective positive response in a patient with hepatitis B surface antigen (HBsAg)-negative HCC metastases in the lungs following liver transplant. The patient, described today in a presentation at The International Liver Congress™ 2018 in Paris, France, had a volumetric reduction of almost all lung lesions and no new lesions detected in the lung or liver.

HCC is the most common primary liver cancer and more than 50% of cases around the world are thought to be associated with chronic HBV.1,2 With a poor prognosis and limited therapeutic options, HCC is the second most common cause of cancer mortality worldwide.2,3 Liver transplantation is an option for some patients but HCC recurs in up to 20% of cases,4 with the lungs the most common site of metastases.5,6 Cytotoxic T cells play a key role in killing cancerous and infected cells when TCRs on their surface recognize short epitopes presented on the affected cell’s surface and initiate a series of cytotoxic mechanisms. In HBV-related HCC tumours, integrated HBV DNA can result in both oncogenic transformation and


Article originally posted at

Click here for the full story


Privacy Policy / Terms Of Use

       Powered by MMD